ATG4B Inhibitor UAMC-2526 Potentiates the Chemotherapeutic Effect of Gemcitabine in a Panc02 Mouse Model of Pancreatic Ductal Adenocarcinoma

Resistance against anti-cancer therapy is one of the major challenges during treatment of multiple cancers. Gemcitabine is a standard first-line chemotherapeutic drug, yet autophagy is highly activated in the hypoxic microenvironment of solid tumors and enhances the survival of tumor cells against gemcitabine chemotherapy. Recently, we showed the add-on effect of autophagy inhibitor UAMC-2526 to prevent HT-29 colorectal tumor growth in CD1-/- Foxn1nu mice treated with oxaliplatin. In this study, we aimed to investigate the potential beneficial effects of UAMC-2526 in a syngeneic Panc02 mouse model of pancreatic ductal adenocarcinoma (PDAC). Our data showed that UAMC-2526 combined with gemcitabine significantly reduced tumor growth as compared to the individual treatments. However, in contrast to in vitro experiments with Panc02 cells in culture, we were unable to detect autophagy inhibition by UAMC-2526 in Panc02 tumor tissue, neither via western blot analysis of autophagy markers LC3 and p62, nor by transmission electron microscopy. In vitro experiments revealed that UAMC-2526 enhances the potential of gemcitabine to inhibit Panc02 cell proliferation without obvious induction of cell death. Altogether, we conclude that although the combination treatment of UAMC-2526 with gemcitabine did not inhibit autophagy in the Panc02 mouse model, it has a beneficial effect on tumor growth inhibition.

[1]  Eugene J Koay,et al.  Early Detection of Pancreatic Cancer: Opportunities and Challenges. , 2019, Gastroenterology.

[2]  Jian Kang,et al.  The independence of and associations among apoptosis, autophagy, and necrosis , 2018, Signal Transduction and Targeted Therapy.

[3]  Min Li,et al.  ATG4B inhibitor FMK-9a induces autophagy independent on its enzyme inhibition. , 2018, Archives of biochemistry and biophysics.

[4]  John Calvin Reed,et al.  Drug Repurposing Screening Identifies Tioconazole as an ATG4 Inhibitor that Suppresses Autophagy and Sensitizes Cancer Cells to Chemotherapy , 2018, Theranostics.

[5]  C. James,et al.  MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma , 2017, Cancer cell.

[6]  G. D. De Meyer,et al.  ATG4B inhibitors with a benzotropolone core structure block autophagy and augment efficiency of chemotherapy in mice , 2017, Biochemical pharmacology.

[7]  Jungwon Choi,et al.  Autophagy is required for PDAC glutamine metabolism , 2016, Scientific Reports.

[8]  S. Leung,et al.  Identification of breast cancer cell subtypes sensitive to ATG4B inhibition , 2016, Oncotarget.

[9]  L. Wood,et al.  Pancreatic cancer , 2016, The Lancet.

[10]  L. Ouyang,et al.  Unraveling the roles of Atg4 proteases from autophagy modulation to targeted cancer therapy. , 2016, Cancer letters.

[11]  Hanlee P. Ji,et al.  Pan-cancer analysis of the extent and consequences of intratumor heterogeneity , 2015, Nature Medicine.

[12]  K. Ross,et al.  Transcriptional control of the autophagy-lysosome system in pancreatic cancer , 2015, Nature.

[13]  H. Kuramoto,et al.  The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition. , 2015, Gynecologic oncology.

[14]  Xindao Yin,et al.  The Reverse Warburg Effect and 18F-FDG Uptake in Non–Small Cell Lung Cancer A549 in Mice: A Pilot Study , 2015, The Journal of Nuclear Medicine.

[15]  Charles Swanton,et al.  Translational Implications of Tumor Heterogeneity , 2015, Clinical Cancer Research.

[16]  K. Guan,et al.  mTOR: a pharmacologic target for autophagy regulation. , 2015, The Journal of clinical investigation.

[17]  A. Ballabio,et al.  Lysosome: regulator of lipid degradation pathways , 2014, Trends in cell biology.

[18]  Xiao-Ming Yin,et al.  A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors , 2014, Autophagy.

[19]  Hui Mi Wang,et al.  The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells. , 2014, Blood.

[20]  A. Troxel,et al.  A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme , 2014, Autophagy.

[21]  A. Civelek,et al.  18F-Fluorodeoxyglucose Uptake and Tumor Hypoxia: Revisit 18F-Fluorodeoxyglucose in Oncology Application , 2014, Translational oncology.

[22]  Y. Ohsumi.  Historical landmarks of autophagy research , 2013, Cell Research.

[23]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[24]  Z. Huang,et al.  Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment , 2013, Cell Death and Disease.

[25]  M. Roberge,et al.  The Autophagy Inhibitor Verteporfin Moderately Enhances the Antitumor Activity of Gemcitabine in a Pancreatic Ductal Adenocarcinoma Model , 2013, Journal of Cancer.

[26]  E. Cuyás,et al.  The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer , 2013, Scientific Reports.

[27]  B. Rothermel,et al.  Cardiovascular autophagy , 2013, Autophagy.

[28]  P. Agostinis,et al.  Autophagy: shaping the tumor microenvironment and therapeutic response. , 2013, Trends in molecular medicine.

[29]  Wei-dong Hu,et al.  Application and interpretation of current autophagy inhibitors and activators , 2013, Acta Pharmacologica Sinica.

[30]  P. O'dwyer,et al.  Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy , 2013, Clinical Cancer Research.

[31]  D. Rubinsztein,et al.  Autophagy and neurodegeneration. , 2012, The Journal of clinical investigation.

[32]  E. White.  Role of autophagy in cancer , 2012 .

[33]  Shengrong Sun,et al.  An autophagy inhibitor enhances the inhibition of cell proliferation induced by a proteasome inhibitor in MCF-7 cells. , 2011, Molecular medicine reports.

[34]  K. Garber.  Inducing indigestion: companies embrace autophagy inhibitors. , 2011, Journal of the National Cancer Institute.

[35]  Z. Shao,et al.  Kinetics Comparisons of Mammalian Atg4 Homologues Indicate Selective Preferences toward Diverse Atg8 Substrates* , 2010, The Journal of Biological Chemistry.

[36]  Eileen White,et al.  Autophagy and Metabolism , 2010, Science.

[37]  M. Gerlinger,et al.  How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine , 2010, British Journal of Cancer.

[38]  Z. Dong,et al.  Autophagy is a renoprotective mechanism during in vitro hypoxia and in vivo ischemia-reperfusion injury. , 2010, The American journal of pathology.

[39]  Nahum Sonenberg,et al.  Dissecting the role of mTOR: lessons from mTOR inhibitors. , 2010, Biochimica et biophysica acta.

[40]  W. Scheithauer,et al.  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Kojima,et al.  Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome , 2008, Cancer science.

[42]  T. Lawrence,et al.  Chemoradiotherapy for unresectable pancreatic cancer , 2008, International Journal of Clinical Oncology.

[43]  A. Apel,et al.  Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. , 2008, Cancer research.

[44]  R. Tehrani,et al.  Ocular Toxicity of Hydroxychloroquine , 2008, Seminars in ophthalmology.

[45]  Y. Ohsumi,et al.  Atg8, a Ubiquitin-like Protein Required for Autophagosome Formation, Mediates Membrane Tethering and Hemifusion , 2007, Cell.

[46]  Michael T. Lotze,et al.  Inflammation and necrosis promote tumour growth , 2004, Nature Reviews Immunology.

[47]  H. Kalthoff,et al.  Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria‐mediated apoptosis , 2004, International journal of cancer.

[48]  Y. Nakajima,et al.  Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. , 2003, Anticancer research.

[49]  A. Sehgal.  Anticancer drug discovery using chemical genomics. , 2003, Current medicinal chemistry.

[50]  A. Koong,et al.  Pancreatic tumors show high levels of hypoxia. , 2000, International journal of radiation oncology, biology, physics.

[51]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[52]  Cassandra Wasson,et al.  Cardiovascular , 1999, Blood Purification.

[53]  J. Kleeff,et al.  Pancreatic cancer , 1988, Nature Reviews Disease Primers.

[54]  F. Schabel,et al.  Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. , 1984, Cancer research.

[55]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[56]  G. D. De Meyer,et al.  Methods to assess autophagy in situ--transmission electron microscopy versus immunohistochemistry. , 2014, Methods in enzymology.

[57]  A. Alavi,et al.  Opportunities and Challenges , 1998, In Vitro Diagnostic Industry in China.

[58]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.